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Abstract: Every living organism on earth owes its viability to its different sizes of nanostructures and the interaction of
these structures at the nano size. Nanotechnology gives us an opportunity to understand nanoscale processes in living
organisms and interfere with and manipulate them. Today, biocompatible nanosized structures are designed by applying
developments in nanotechnology to biomedicine; thus, therapeutic agents are available to reach diseased tissues and
even cells. However, it is essential that nanomaterials that would be used for therapeutic aims be targetable to diseased
areas and have low toxicity. In addition, these nanomaterials must have high biocirculation and pharmacokinetic
properties. Compared to conventional methods, gold nanoparticles (AuNPs) have the appropriate physical, chemical,
mechanical, optical, and electronic properties for the design of nanobiomaterials that exhibit high selectivity, specificity,
and sensitivity in the early detection, diagnosis, and treatment of diseases. Recently, gold has been used in prominent
drug and gene carrier platforms because it binds various therapeutic agents and biomolecules in a stable way to create
biocompatible complex structures. In addition, it has nontoxic nuclei and surface properties such as charge and
hydrophobicity, which are adjustable in a monolayer. In the near infrared region, AuNPs are effective probes for in
vivo and in vitro imaging with their high plasmon resonance absorption and scattering. In addition, their ability to
rapidly convert optical energy to heat energy enables the ablation of invasive cancer tissues photothermally, even at a
low power. This review sheds light on the synthesis, surface functionality, and potential applications of colloidal AuNPs
in biomedicine.
Key words: Gold nanoparticles, colloidal gold, nanotechnology, nanostructures, nanobiomaterials, biomedicine,
cancer, photothermal therapy

Introduction
Nanomedicine is a discipline recently developed
through the introduction of nanotechnology in
medicine. One of the main purposes of nanomedicine
is to develop structures with biocompatibility at a
nanoscale that will facilitate the access of therapeutic
elements to diseased tissues and cells. Pioneering
studies in this field include research into fabrication,
characterization, and molecular mechanisms,
followed by the development of new nanostructures
and nanodevices that can be used in imaging,

detecting (biosensors), and targeting (drugs and
genes) applications (Figure 1).
Some of the challenges confronting conventional
treatment methods are intrinsic toxicity and low
bioavailability (1). These challenges significantly
reduce the therapeutic impact of drugs. Nanoscale
systems in the form of supramolecular structures,
complexes, or composites can surround drug
molecules and convey the therapeutic agents directly
to the diseased region, thus minimizing the toxicity
level of the system (2).
607
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Nanotechnological drug delivery systems carry
drugs to the target region in the body. Delivery
can be made through active or passive routing (3).
Therapeutic chemicals carried to the diseased region
will not make contact with healthy tissues and thus
will not damage healthy tissues (3,4). Drug delivery
systems based on nanotechnology differ from
conventional drug delivery systems in certain ways.
Such differences arise from the size of the delivery
molecules in the solutions used. Due to their size, i.e.
a billionth or 10−9 of a meter, these particles exhibit
new physicochemical features. In delivery systems
at micro levels, targeting is limited by the physical
characteristics of the capillary beds. This new sizing

at nano levels makes the chemical to be targeted
in the delivery system even freer and renders the
selection of targeted tissue more specifiable with
surface characteristics. By these means, the delivery
of therapeutic agents into specific cells and the
diagnosis and cure of diseases occurs at the cellular
level (5). However, in addition to biocirculatory and
pharmacokinetic properties of these materials used
as the drug delivery system, the location and time of
release of the carried drug molecules are extremely
important. It is also expected that these materials will
cause no toxicity and be easily discharged from the
system.

Nuclear targeting
(oligonucleotide, peptides (NLS, TaT, etc.))

Ex vivo, in vivo imaging
(OCT, PAT, Raman)

Abnormal cell

Drug delivery
(paclitaxel TNF-α, MTX)

Cancer treatment
(phototherapy, radio/photo sensitizer)

Figure 1. Biomedical applications of gold nanoparticles. This figure inspired by ref. 12 and 17.
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Why nanogold?
Although there are many nanotechnological
structures used in drug targeting and controlled
release, gold nanoparticles (AuNPs) hold a special
place. Gold is a noble metal and has nontoxic
characteristics (6). It is stable to oxidation compared to
other metals (7) and is not easily affected by an acidic
environment (8). AuNPs can be readily modified
with ligands containing functional groups such as
thiols, phosphines, and amines to anchor the ligands,
and additional moieties such as oligonucleotides,
proteins, and antibodies can be used to impart even
greater functionality (9). When directed into the
cell, AuNPs cause very low cytotoxic effects without
damaging healthy cells (10,11) depending on the
capping agent used in the synthesis procedure.
AuNPs enable the adjusting of surface features such
as charge and hydrophobia without interaction with
any other covering agent (12).
AuNPs interact with the thiol (-SH) group, which
is easily linked with biomolecules, and provide
selectivity in nuclear targeting (gene carrying,
antisense treatment) applications. The targeted
nanoparticles release their therapeutic payloads
in the target tissues and cells through intracellular

interaction [e.g., pH (13), glutathione (14)] or
external stimuli [e.g., light (15)] (Figure 2).
Due to surface modification, in vivo
pharmacokinetics,
biopropagation,
and
the
circulation period of biomolecules based on
AuNPs will be enhanced (18). Ligands attached to
the nanoparticle surface interact with membrane
receptors and enable nanoparticles to penetrate
from the cell membrane into the cytoplasm. For
this reason, the ligand number on the nanoparticle
surface is very important during the penetration of
nanoparticles from the cell membrane. Murray et al.
(1998) prepared dodecanethiolate-stabilized AuNPs
with core sizes from 1.5 to 5.2 nm, and at this range
the Au core contained an average of approximately
110−4800 Au atoms and from 53 to nearly 520
alkanethiolate chains in the monolayer (19). Gibson
et al. succeeded in coupling approximately 70
molecules of paclitaxel, a chemotherapeutic drug, to
a AuNP with 2-nm core sizes (20).
A plasmon is a collective oscillation of free
electrons in the conduction band of metals stimulated
by incident light. It is an optical fact resulting from
the interaction between electromagnetic waves and
metal surface electrons. When a metal absorbs light

Ligand exchange

Nucleus
Lower pH

Figure 2. The therapeutic agents carried by AuNPs are released through low pH,
glutathione (GSH), or stimulation with radiation (16).
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Figure 3. AuNPs can be conjugated with many different
molecular structures (17).

at a resonant wavelength, it causes the electron cloud
to vibrate and spread the energy. This vibration
spreads just like the propagation of an acoustic
vibration harmonically generated by a stringed
instrument (plasmon resonance). For metals,
plasmon resonance is seen in the infrared region; for
AuNPs, it is seen in both the visible (the interval that
may be perceived by eye) and infrared regions (21).
In addition, AuNPs create strong light absorption
and scattering at plasmon wavelength (22,23). This
strong light scattering enables AuNPs to show high
specificity and sensitivity in diagnostic and sensing
applications. Yet another advantage of AuNPs is
their ease of synthesis; monodisperse AuNPs can
be formed in various shapes including nanosphere,
nanorod, and nanocube with core sizes ranging from
2 to 150 nm (24−26).
Photothermal features of AuNPs
The electrons in metal are not bound to individual
atoms; instead, they form a cloud around the atomic
core (Figure 4).
The mobile electron cloud enables metals to
transfer their charges easily. Due to this feature, the
conductivity of metals is high. This also explains
why metals shine; light hitting the electron cloud
surrounding metal surfaces reflects back to our
eyes. Since atomic cores are blocked by the electron
610

Figure 4. The electron cloud surrounding metals prevents
incident light from being absorbed by the nucleus.

cloud, they do not absorb photons. Consequently, the
brightness of metals is associated with the photons
reflecting back to our eyes. As we further know from
quantum mechanics, electrons can behave as waves
or particles. If we consider the electrons inside an
electron cloud as waves within a certain energy value,
we can envision a situation where it is possible for
light of the same wavelength to be absorbed by the
electron cloud and move through the electron cloud
by producing resonance. When a metal absorbs
light at the length of the resonance wavelength, this
causes the electrons to vibrate and scatter energy.
This process generally occurs on the surface of
metals. It continues through the electron cloud and
is therefore called surface plasmon resonance. The
name ‘plasmon’ originates from the oscillations of the
electron cloud (27).
Gold nanostructures with surface plasmon
resonance have become prominent in optical imaging
applications owing to their strong light absorption
and scattering in the visual and near infrared portion
of the spectrum (28−32). These optical skills, which
depend on the size, shape, and dielectric constant
of nanoparticles (33−36), enable applications where
particles are used as imaging and sensing probes.
AuNPs can also convert optical energy into heat
via nonradiative electron relaxation dynamics (37),
which endows them with intense photothermal
properties. The regional heating effect constitutes
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Scattering

Heat

Light

Figure 5. The photophysical process occurring in gold nanorods.
Absorbance of near infrared irradiation usually induces
longitudinal plasmon resonance mode. Heat is also generated
as a consequence of electron−phonon collisions (37).

a noninvasive alternative to surgery for directly
removing diseased tissue (Figure 5) (38).
Nanostructures such as rods, spheres, shells, and
cages are intensively used for removing cancer cells
photothermally (39). Briefly, AuNPs are promising
tools for photothermolysis because they have unique
optical features such as light absorption and photo
stability.
Synthesis of AuNPs
AuNPs with core sizes ranging from 2 to
150 nm synthesize by reducing hydrogen
tetrachloroaurate(III) (HAuCl4) solution controlled
by different reducing agents; this leads to the
nucleation of Au ions to nanoparticles under certain
conditions. Citrate is used as the most common
reducing agent in this synthesis process, and the
synthesized AuNPs are almost the same type and size
(Figure 6) (40).

Citrate is used as both the anionic stabilizer and
reducing agent in this process, which is known as the
Turkevich method. Particles with diameters ranging
from a few to several hundred nanometers in diameter
can be obtained by controlling the gold-to-citrate
ratio (41). In general, to produce bigger particles,
less sodium citrate is added to the media. The biggest
drawbacks of this method are low productivity and
the need to use water as a solvent.
Another common method for AuNP synthesis is
biphasic reduction of HAuCl4 by sodium borohydride
(NaBH4) in the presence of thiol capping agents,
inspired by Faraday’s 2-phase system from 1857
(42,43). With this method, the core size of particles
varies from 1.5 nm to about 5 nm and can be
controlled by adjusting the gold-to-thiol ratio.

Figure 6. Citrate-stabilized AuNPs.
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Biomedical application areas
The use of gold salts in medicine, or chrysotherapy,
dates back to ancient times. Ancient cultures in
Egypt, India, and China used gold to treat diseases
such as smallpox, skin ulcers, syphilis, and measles
(44). Today, gold is used in medical devices including
pacemakers and gold plated stents (45), middle ear
implants (46), and the gold implants and alloys used
in dental restoration (47). More recently, several
organogold complexes have emerged with promising
antitumor, antimicrobial, antimalarial, and antiHIV activities (48). In addition, it is well known that
organogold compounds are still widely used for the
treatment of rheumatoid arthritis (49). Organogold
compounds relieve symptoms of arthritis such as
joint pain, stiffness, swelling, and bone damage
and also reduce the chance of joint deformity
and disability. However, the toxicity of many of
organogold compounds is dose-dependent. Arthritis
patients undergoing chrysotherapy often experience
2 common side effects: proteinuria and skin reactions
(50).
Kogan et al. removed β-amyloid fibrils and plates,
which are thought to be associated with Alzheimer
disease, by using AuNPs during in vitro experiments
(51). In that study peptide−gold nanoconjugates
selectively attached to β-amyloid protein, and after
a 48-h incubation period amyloidogenic aggregates
were irradiated by weak microwaves for 8 h. After
irradiation, fibrils were mostly removed. The use of
AuNPs reduced the required microwave energy to a
level 6 times lower than normal, and healthy cells were
not damaged during treatment. The treatment was
effective at breaking up the fibrils and also resulted
in a lower tendency of the proteins to reaggregate for
at least 1 week after being irradiated. With reference
to the same approach, researchers are working on
the treatment of other neurodegenerative diseases
involving protein aggregation, including Parkinson
disease and Huntington disease (51).
AuNPs, which are used for treatment of ocular
diseases, are especially preferred for carrying
therapeutic agents to regions under the retina.
Diseases such as ocular angiogenesis, diabetic
retinopathy, and neovascular maculopathy can
612

harm eyesight. As a result of recent studies, it was
determined that after intravitreal injection of the
antivascular endothelial growth factor (anti-VEGF)
antibody, ocular angiogenesis was significantly
prevented (52). The use of AuNPs for carrying the
anti-VEGF antibody and other angiogenesis agents
to specific places in the eye has produced much more
effective results (53).
AuNPs are used for the encapsulation of
hydrophobic anticancer drugs such as paclitaxel,
cisplatin, and doxorubicin in order to avoid the
mononuclear phagocyte system (54). In addition
to cytostatics, AuNPs can be used as carriers of
antiparasitic and antiinflammatory drugs, pilocarpine,
and insulin; they are also used as helpers for enzymes
and vaccines (55). The supporting effects of AuNPcarrying antigens are promising in immunology
(56). In the case of delivery of antiinflammatory
benefits by nanoparticles, the resulting effects rose
to be 10 times greater (57). In particular, it was
proven that with nanoparticles plasma glucose levels
decreased for the oral administration of insulin
(58). The chemotherapy, radiotherapy, surgery, and
hormonotherapy used in cancer treatment cause
significant side effects such as nausea, vomiting,
and hair loss (59); due to the prolonged duration
of treatment, alternative treatment methods are
needed. In particular, the anticancer drugs used in
chemotherapy, one of the most regularly applied
cancer treatment methods, affect cancer cells but also
harm healthy cells (60).
AuNPs are used to increase drug specificity
and the effectiveness of noninvasive treatments;
they also contribute to healing side effect profiles.
Targeting tumor cells allows for the diagnosis
and early recognition of disease and, in tandem
with monitoring tumoral propagation by optical,
thermal, or thermoacoustic imaging, makes the
destruction of these tumoral cells photothermally
possible (61,62). AuNPs are not only targeted to
specific cell lines; they can also be targeted to specific
intracellular compartments such as the nucleus
(63−65), mitochondria (66), and the Golgi apparatus
and endoplasmic reticulum (67). In particular, the
nucleus can be targeted by AuNPs used as gene
carriers so that damaged genes are treated.

G. TAN, M. A. ONUR, N. SAĞLAM

Cancer treatment
It is very important to understand the difference
between normal tissues and cancerous tissues in
order to develop effective hybrid nanoparticles for
cancer identification and diagnosis. Normal tissues
have tight, continuous vessel walls with pores that are
approximately 9 nm in diameter and 50-nm pores
that are 100–1000 times fewer in number than the
9-nm pores (68). Small molecules can easily penetrate
all types of tissues in contrast to large molecules,
such as microstructures, which do so very slowly.
However, tumor tissues, inflammatory tissues, and
reticuloendothelial system (RES)-rich organs such
as the liver, spleen, and bone marrow, which have
discontinuous capillary walls, allow particles of less
than 100 nm to penetrate easily. This is because their
discontinuous capillary walls have a large number of
pores that are approximately 100 nm in diameter and
no basal lamina. This leads to enhanced penetration of
particles of 50−100 nm in tissues and organs that have
discontinuous capillary walls (Figure 7) (69). Tumor
tissues are deprived of the lymphatic system, which is
used to suspend lipophilic and polymeric materials
from the body (69). Therefore, once nanoparticles
penetrate into tumor tissue, they cannot be easily
removed. In addition, tumors exhibit enhanced
penetration and retention effect for particles of

50−100 nm (70). Thus, hybrid nanoparticles from
50 to 100 nm are well suited for targeting tumors for
imaging and therapeutic purposes.
Paciotti et al. conducted in vivo research to
investigate the effects of gold colloidal attached with
tumor necrosis factor (TNF) and polyethylene glycol
(PEG). TNF has therapeutic properties for both the
targeting and destruction of cancer cells. They also
indicated that AuNPs attached with TNF are more
effective for the reduction of MC-38 colon carcinoma
tumor mass than TNF alone (71). In addition, cAuPEG-TNF complexes intravenously injected into
mice were observed to collect in MC-38 colon
carcinoma tumors more widely than in liver, spleen,
and other healthy cells (72).
Many cancer cells have a receptor known as the
epidermal growth factor receptor (EGFR), which is
propagated in the outer surface of cell membranes.
Normal cells do not have this receptor (73). El-Sayed
et al. attached antibodies known as anti-EGFR to
AuNPs against EGFR protein and developed a new
weapon against cancer cells. In that study, 2 oral
squamous carcinoma cell lines (HSC313 and HOC3
clone 8) and a benign epithelial cell line (HaCaT9)
were incubated with AuNPs attached to the antiEGFR, and then they were exposed to a 514-nm
wavelength of a visible argon ion laser (73).

Figure 7. Particle penetration into tumor capillaries (68).
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As a result of that study, it was determined that
the energy level required to destroy malignant cells
after the incubation of AuNPs with anti-EGFR was
very low (approximately one-half) compared to
benign cells (73). In addition, under the appropriate
laser radiation conditions (19−32 W/cm2), tumor
cells were destroyed without harming healthy cells
through the use of AuNPs. In light of these results,
it is clear that AuNPs have become prominent as a
new type of selective photothermal agent under
continuous-wave laser radiation at low power.
Nuclear targeting and gene delivery
Targeted admission into cells is an increasingly
important research area. In intracellular targeting,
the nucleus in particular is a desirable target
because the genetic information of the cell and
transcription machinery resides there. Diagnoses of
disease phenotype, identification of potential drug
candidates, and treatment of disease by novel methods
such as antisense therapy would be enhanced greatly
by the efficient transport of materials to the living cell
nuclei (74).
Targeted nuclear delivery is a challenging task,
as any nuclear probe must satisfy the following
minimum requirements (75) and be able to:
1. cross the cellular membrane directly or
bind to specific plasma membrane receptors, as in
receptor-mediated endocytosis (RME),
2.

escape endosomal/lysosomal pathways,

3. possess a nuclear localization signal (NLS) to
interact with the nuclear pore complex,
4. be small enough to penetrate cells and cross
the nuclear membrane (<100 nm for uptake by RME
and <30 nm for import through nuclear pores), and
5.

have low toxicity.

In biology, the most efficient nuclear targeting
is accomplished by viruses, which commonly
utilize different peptides for crossing each cellular
membrane barrier.
In the pioneering work in this field, Feldherr and
Akin studied the nuclear translocation of AuNPs
carrying peptides from the SV40 large T antigen;
they used microinjection or chemically modified
cells, thus bypassing cellular membrane entry (76).
614

Zhao et al. derivatized supermagnetic
nanoparticles carrying HIV TAT peptides (77). TAT
peptides are generic translocation peptides, and
when conjugated to magnetic nanoparticles, effective
nuclear targeting was achieved for the investigated
HeLa cell line.
Tkachenko et al. conducted a study to identify
the most capable peptides for accomplishing each
of the tasks stated above and then combined these
peptides on a single nanometer-sized platform. They
chose AuNPs of 20 nm in diameter as the platform.
The gold particle was modified with a shell of bovine
serum albumin (BSA) conjugated to various cellular
targeting peptides (78). AuNPs attached to different
peptide series were explored to achieve nuclear
targeting in intact HepG2 cells. They chose HepG2
cells instead of the HeLa cell lines, which were used
in many studies due to the difficulty of membrane
translocation. In that study, BSA-AuNP-peptides
were incubated with the HepG2 cell line for 2 h,
and then a color video microscope and differential
interference contrast microscopy combination was
used to monitor the trajectories of the particles inside
cells.
As a result of this nucleus localization study, it
was observed that AuNPs conjugated with peptide
#1 (CGGGPKKKRKVGG), which was derived
from SV40 large T antigen and had a nucleus
localization signal that was internalized via RME;
however, it was unable to escape the endosome
and target the nucleus. Particles conjugated with
peptide #2 (CGGFSTSLRARKA), which was
derived from adenoviral fiber protein and had a
nucleus localization signal, could not enter HepG2
cells. The particles conjugated with peptide #3
(CKKKKKKSEDEYPYVPN), which originated from
adenoviral protein and contained RME, entered the
cell (B) but remained trapped in endosomes and did
not reach the nucleus. The particles carrying peptide
#4 (CKKKKKKKSEDEYPYVP-NFSTSLRARKA),
which was obtained from adenoviral fiber protein
formed with a long single peptide chain including
both RME and NLS, managed to target the nucleus;
however, nanoparticles carrying peptides #2 and #3
had a greater propensity for nuclear targeting than
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any other single peptide explored (78). In view of
these results, the nanoparticle complex must present
both RME and NLS peptides to enter intact HepG2
cells and achieve nuclear localization (78). The
origin of the higher nuclear targeting efficiency in
nanoparticles carrying 2 short peptides versus 1 long
sequence could be structural or spatial. Thus, when 2
short peptides are attached to a single nanoparticle, it
is likely that the individual targeting signals are more
accessible to cellular receptors (78).
Kamei et al. attached gold/iron-oxide magnetic
nanoparticles (GoldMAN) to the adenovirus gene
delivery vector (Ad) via thiol (-SH) or disulfide (SS) functional biomolecules and then directed these
hybrid particles at the melanoma cell line (B16BL6)
by targeting inside the nucleus (79). Adenovirus
vectors are commonly used for in vitro and in vivo
gene transfers due to their high transduction effect
(Figure 8) (79).
GoldMAN imparts useful magnetic properties
to various biomolecules. AuNPs immobilized on
the surface of magnetic nanoparticles allow for the
conjugation of biomolecules via an Au–S bond.
Kamei et al. performed a practical application by
utilizing GoldMAN and a magnetic field to induce
intracellular transduction. Their method has great

potential for the application of Ad, widely used for in
vitro and in vivo gene transfer, to Ad-resistant cells.
They demonstrated that Ad was easily immobilized
on GoldMAN, and the Ad/GoldMAN complex
was introduced into the cell by the magnetic field,
which increased gene expression to over 1000
times the expression produced by Ad alone. The
GoldMAN penetrated the plasma membrane
directly, independent of the cell surface virus
receptors and endocytosis pathway. This mechanism
will contribute to improving the gene expression
efficiency of Ad. This technology is a useful tool for
extending Ad tropism and enhancing transduction
efficiency. GoldMAN also makes effective use of
various biomolecules within the cell possible due to
its interesting cell entry mechanism (79).
The effect of AuNPs and ligand type on cellular
uptake
Targeting specific tissues or cells can be achieved by
type-specific ligand types linked to AuNPs. Bergen et
al. linked thiol-PEG and o-pyridyl disulfide (OPSS)PEG-galactose ligand to AuNPs of different sizes
(50, 80, 100, and 150 nm) and directed them to liver
hepatocyte and nonparenchymal cells (NPCs) (80).
The results 2 h after injection were impressive (Figure
9).

Formation of GoldMAN/viral complex by Au-S bond

Nuclear

Figure 8. Schematic illustration of gene delivery with GoldMAN
(79).

Figure 9. AuNPs functionalized by linking PEGs and targeting
ligands (galactose).
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In AuNP ligand nanoconjugation, AuNP-PEGgalactose complexes exhibited more specificity than
AuNP-PEG or AuNPs alone. In particular, 50-nm
AuNPs and AuNP-PEG-galactose particles were
internalized by liver hepatocyte and NPC at the
highest ratio (80).
Latest developments in AuNP design
Designing controlled drug delivery platforms that
allow for management of location and timing of
drug release under physiological conditions remains
a challenge. In particular, when nanoparticles carry
or encapsulate toxic pharmaceutical payloads, zero
premature release and stimuli-responsive controlled
release of the precious and often toxic pharmaceutical
cargo are 2 important prerequisites that impact
therapeutic efficacy and cytotoxicity (81).
Parallel to advances in nanoparticulation
technology, new developments are taking place in
drug delivery platforms. One of the innovations
in this field is the mesoporous silica nanosphere
(MSN)-based controlled-release system. MSN with
blocked pores throw off pore-blocking caps and
release their guest molecules, such as drug or gene
molecules, into the target environment at timely
intervals via stimulating invasive and externally
controllable triggers. Using nanoparticles, organic
molecules, or supramolecular assemblies as poreblocking caps, these spheres ensure zero premature
release. Vivero-Escoto et al. achieved the synthesis of

a AuNP-capped MSN material for the photoinduced
intracellular controlled release of an anticancer drug,
paclitaxel, inside human fibroblast and liver cells
(Figure 10) (81).
Vivero-Escoto et al. first functionalized the
surface of the AuNP with a photo-responsive
linker,
thioundecyl-tetraethyleneglycolester-onitrobenzylethyldimethyl ammonium bromide
(TUNA). The capping mechanism of MSN pores is
based on electrostatic interaction between positively
charged, photosensitive gold nanoparticles (PRAuNPs) and negatively charged (zeta potential =
−23.8 ± 1.8 mV) MSN in water. The uncapping
mechanism of pores is the photolabile linker
covalently attached to the surface of PR-AuNPs,
which would be cleaved upon photoirradiation as
a result of the formation of a cationic compound
(1) (Figure 10) as well as the negatively charged
thioundecyltetraethyleneglycolcarboxylate (TUEC)functionalized AuNPs (NC-AuNPs). In summary,
AuNPs with surface charges that transform from
positive (PR-AuNPs) to negative (NC-AuNPs) via
photoexcitation leave from MSN pores, and MSN
releases drug molecules inside the outer medium
(81).
Together with recent improvements in controlled
drug release mechanisms, studies on developing
delivery platforms that can release more than one
therapeutic agent at different times are ongoing.

Figure 10. A schematic representation of intracellular controlled release of photoinduced
PR-AuNP-MSN (81).
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Figure 12. Cisplatin-Au-Fe3O4-Herceptin nanoparticles acting
as special nanocarriers are targeted and carry out
cisplatin release to Her2-positive breast cancer cells
(83).

the body. The new system is controlled externally and
could theoretically deliver up to 3 or 4 drugs (82).
Figure 11. Nanocapsules and nanobones will perform the
controlled release of many therapeutic agents by
melting at different wavelengths of infrared beams
(82).

Hamad-Schifferli synthesized AuNPs in the form
of capsules and bones and designed a drug delivery
system that enables the control of a multidrug
transport system under infrared radiation (82).
Through this study of controlled multidrug release,
it may be possible to produce a synergistic effect with
more than one drug for many diseases, in particular
cancer and AIDS. Current drug delivery devices can
release a maximum of 2 drugs at different times;
however, the timing of the release must be built into
the device, and it cannot be controlled from outside

The underlying idea of Hamad-Schifferli’s study
is that nanoparticles of different shapes respond
to different infrared wavelengths and release drug
payloads bonded onto their surfaces. In this context,
the research team succeeded in building 2 different
nanoparticle shapes: nanobones and nanocapsules.
Nanobones melt at light wavelengths of 1100 nm, and
nanocapsules melt at wavelengths of 800 nm (Figure
11) (82).
Another important development in this field was
a drug delivery system consisting of gold and ironoxide nanoparticles that targeted Her2-positive breast
cancer cells designed by Xu et al. They developed
dumbbell-like Au-Fe3O4 nanoparticles, and in this
form they anchored a platin complex on the Au
side by reacting Au-SCH2CH2N (CH2COOH)2 with

Extracellular environment
(ph=7.4)

Figure 13. Cisplatin-Au-Fe3O4-Herceptin nanocomplex breaks its cisplatin−Au link at a
low pH in a lysosomal environment. The free cisplatin molecules are located
in nuclear regions (83).
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Figure 14. Scheme of the layer-by-layer technique, which is based on covering AuNPs
with cationic and anionic electrolytes, and transmission electron microscopy
images of AuNP with a 13.5-nm diameter capped by 20 layers of PAH/PSS
(89).

cisplatin and the Her2-specific monoclonal antibody
Herceptin (targeting agent); this was linked to the
iron-oxide side through PEG3000-CONH-Herceptin
(Figure 12) (83).
Once the particles penetrate the cell, as a result
of the low pH, cisplatin molecules leave the AuNPs.
After the cisplatin enters the cellular system, it is
hydrolyzed and becomes small particles; later, it
penetrates into nuclear regions and interacts with
DNA (Figure 13) (83).
Conclusion
New nanotechnological applications have created
a breakthrough in material science through
nanoparticles. Although different methods are
applied in order to develop functionalized AuNPs
for use as cellular probes or delivery agents, the
inability to maintain the colloid stability necessary
to carry therapeutics (drugs, biomolecules) and the
aggregation of particles caused by contrast agents are
still challenges (84).
Typically, in the presence of reducing agents
such as sodium citrate and sodium borohydride, the
colloidal stability efficiency of synthesized AuNPs
increases. On the other hand, surface functionality
of particles is limited. In order to enhance surface
functionality and prevent aggregation, various
capping agents [PEG, cetyltrimethylammonium
bromide (CTAB), thiol groups, and polyelectrolytes]
are used (85).
The aggregation of AuNPs is reduced to a
minimum by means of a technique, sometimes
called layer-by-layer, which is based on coating the
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gold core with cationic and anionic polyelectrolytes
more than once; thus, AuNPs become appropriate
for biological applications. In the presence of a
sodium citrate reducing agent, the surface charge of
prepared AuNPs, depending on shape characteristics
and the Au/citrate rate, varies on average between
−55 mV and −20 mV (86,87). Due to this negative
surface charge, AuNPs can be capped with cationic
polyelectrolyte [poly(allylamine hydrochloride)]
via electrostatic interaction. In this case, the surface
charge of the AuNPs is changed from a negative to
a positive value, and proper conditions are created
to cover AuNPs with an anionic polyelectrode
[poly(styrene sulfonate)] (Figure 14). Since these
interactions are performed in liquid, covering
productivity is increased (88).
AuNPs used in biological applications are
covered with up to 20 layers through this technique,
and the resistance to aggregation is increased. In
addition, combining photosensitive supramolecular
attachment between layers and releasing anticancer
drugs at targeted regions photodynamically has
become a prominent new approach in cancer
treatment.
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